prospectively included in the study. A sample removed from tumours sent for intraoperative examination was frozen at -25°C with polyvinyl alcohol and polyethylene glycol. After the samples evaluated through frozen section were thawed at room temperature, they were fixed in 10% formalin. The routine tissue processing was performed for the frozen and non-frozen sections and they were all embedded in paraffin blocks. Both the frozen and non-frozen sections of each tumour were placed on the same slide. The slides were prepared with five-micronthick tumour tissue. All of the haematoxylin and eosin-stained sections were examined under a light microscope. The samples where the frozen section was analysed before routine tissue processing were classified as the 1st Group. The samples that did not have the frozen section evaluated before routine tissue processing were characterised as the 2nd Group.
Immunohistochemistry
Oestrogen (Thermo, Clone: SP1, 1/400 dilution, Fremont, USA), PR (Dako, Clone: PgR636, 1/150 dilution, Glostrup, Denmark) and c-erB-2 (Dako, Polyclonal, 1/300 dilution, Glostrup, Denmark) primary antibodies were used. A fully automatic immunohistochemical staining device (Ventana BenchMark XT, Ventana Medical Systems, Tucson, USA) containing Biotin-free, HRP multimer-based, hydrogen peroxide substrate and 3, 3'-diaminobenzidine tetrahydrochloride (DAB) chromogen (ultraView ™ Universal DAB Detection Kit, Catalog number 760-500, Ventana Medical Systems, Tucson, USA) was used as the immunohistochemical staining system. Tissue sections were placed on electrostatically charged slides (X-traTM, Surgipath Medical Industries, Richmond, Illinois, USA), and dried at 60°C for at least two hours, followed by the complete IHC staining process, including deparafinisation and antigen releasing processing in the staining device. Only the primary antibodies were manually placed as drops and incubated at 37°C for 30 minutes. All of the slides were evaluated by two pathologists, at least one of whom was experienced in breast pathology. At least 10 high power fields were examined in each tumour section. The rate and intensity of nuclear staining were calculated for ER and PR receptors and complete membranous staining was calculated for c-erbB-2.
Statistical analysis
The statistical analyses were performed with the SPSS software version 19.0 (IBM, New York, USA). The statistical analyses were performed with the statistical package program. The Wilcoxon analysis was used and a p value ≤0.05 was considered significant. This study followed the Declaration of Helsinki on medical protocol and ethics and the regional Ethical Review Board approved the study.
RESULTS
All cases were female and the mean age was 55.26±11.69 (32-81) years. In 33 (62.26%) cases, staining rate and intensity of ER, PR and HER2 were the same for the two groups.
The mean ER staining rate was 56.60±39.56% and 47.08±40.25% in the first and second groups, respectively. The rate was lower in 10 cases and higher in 1 case in the 1st group compared to the 2nd group; the difference between the groups in terms of staining rate was statistically significant (p=0.004). ER staining intensity was the same in both groups in 46 cases, lower in 6 cases and higher in 1 case in the 1st group. However, the difference between the groups was not statistically significant (p>0.05).
The mean PR staining rate was 24.06±31.92% and 18.21±26.51% in the first and second groups, respectively. The rate was lower in 9 cases in the 1st group compared to the 2nd group. The tumour showing a decrease in PR expression in the frozen section is shown in Figures 1, 2 . PR staining intensity was the same in both groups in 47 cases and lower in 6 patients in the 1st group. The difference between the groups for both PR staining rate and staining intensity was statistically significant (p=0.007 and p=0.024, respectively).
The mean HER2 staining rate was 17.36±30.51% and 12.26±27.36% in the 1st and 2nd groups, respectively. The staining rate was lower in 6 cases in the 1st group. The tumour showing a loss of HER2 expression in the frozen section is shown in Figures 3, 4 . HER2 staining intensity was the same in both groups in 47 cases and lower in 6 cases in the 1st group. The difference between the groups for both staining rate and staining intensity was statistically significant (p=0.027 and p=0.020, respectively).
Although various staining rates and intensities were observed in non-frozen sections for ER staining in 3 (5.66%) cases, PR in 2 (3.77%) cases and HER2 in 5 (9.43%) cases, no staining was observed in the corresponding frozen sections. No ER staining was observed in the non-frozen section in one case (1.88%) which indicated expression in the frozen section. The staining rate and intensity of each of the three markers are presented in Tables 1, 2 .
DISCUSSION
Automated staining devices, highly sensitive antibody clones, imaging tests and FDA (U.S. Food and Drug Administration)-approved test kits are currently used as IHC methods in many large centres (5). However, in some pathology laboratories, there are still some problems such as inappropriate fixation, non-optimised methods for obtaining antigens and failure to establish a standard for evaluation (6) (7) (8) . As known, the falsenegative evaluation of hormone receptors in breast carcinomas might lead to the patient not receiving the proper treatment option. Conversely, false-positive results can result in unnecessary treatment complications and increased cost. Tumour tissue selection, the thickness of the section, the antigen release method, the antibody choice and evaluation as well as regular verification of laboratory tests are very important in order to achieve the best results on the IHC evaluation (5, 9-11). Studies of the factors affecting IHC evaluation in breast cancers have focused on the duration of cold ischaemia, the type of fixative, fixative volume and the fixation duration (10, 12, 13) . Prolonged ischaemia is known to decrease ER and PR expression. Khoury et al. (14) reported that breast specimens should be placed in fixation solution for 1 hour and that expression loss starts in the first hour for ER and the second hour for PR. A cold ischaemia duration of 8 hours is reported to result in the complete loss of ER expression, even when the tissue is kept at 4°C. Apple et al. (3) concluded that ER and PR expression were not affected by solution type in their study including 10% formalin, Pen-Fix, Bouin solution, Sakura Molecular fixative, zinc formalin and 15% formaldehyde. Today, the common view is that breast specimens should be fixed with 10% formalin. Although there are various recommendations for formalin fixation duration according to the size of the material (Tru-cut biopsy, partial or total mastectomy etc.), it is commonly believed that fixation for 8-36 hours is required to obtain the best immunohistochemical results (15) (16) (17) (18) . As is already known, loss of immunoreactivity can be seen after "coagulant" fixatives like acetone and ethanol are used (19, 20) . The mechanism of tissue fixation is not well understood, but it is stated that coagulating fixatives lead to dehydration, which decomposes the protein structure by removing free water from the tissue. This situation results in denaturation and a loss of function (21) . In our study, polyvinyl alcohol and polyethylene glycol were used before frozen-section. After frozen-section examination, we obtained 5-micron-thick sections from those tumours that were fixated for at least 8 hours with 10% formalin in our study. We ensured a consistent evaluation by using standards that are commonly accepted worldwide including an automated staining device, sensitive antibody clones, and FDA-approved test kits. We therefore ensured standardisation for all stages except the freezing of tumours before routine tissue processing. Those studies regarding the effect of freezing on immunoexpression often focus on cryopreservation (22, 23) . However, in these studies, tumour tissue frozen in liquid nitrogen and stored at very low temperatures was used. We could not identify any studies about the effect of freezing at higher temperatures on immunoexpression in the literature in English. In our study, the observation of a significant difference between groups in terms of staining for each marker suggests that the frozen examination affects the immunoprofile. As is already known, artefacts may make histological evaluation difficult due to freezing in many tissues. In this study, we observed the negative effect of freezing on histomorphological features and also clearly demonstrated a negative effect of freezing on the immunoprofile. This may have resulted from damage to the protein structure due to the fixatives used or the unknown mechanism of freezing. As the number of cases was not sufficient, we were unable to comment on whether immunoprofile was affected depending on the tumour subgroups. However, the effect of frozen examination on the immunoprofile can be evaluated in detail with studies performed on large series which take the histological subgroups of the tumour into account.
Our study results indicate the negative effect of a frozen examination on hormone receptors and HER2 expression. This result should be taken into account when a frozen examination is required for incisional biopsy or tru-cut biopsy material belonging to patients who are to undergo neoadjuvant treatment or patients with very small tumours.
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